Back to top

Analyst Blog

Eli Lilly (LLY - Analyst Report) and Boehringer Ingelheim recently submitted a New Drug Application (NDA) for their type II diabetes candidate, empagliflozin, in the US. Earlier this year, Eli Lilly and Boehringer Ingelheim had announced positive top-line results on empagliflozin from four phase III trials. Empagliflozin (10 and 25 mg taken once daily), a sodium glucose co-transporter-2 (SGLT-2) inhibitor, was found to be more effective in lowering blood sugar levels compared to placebo.

Meanwhile, the companies also announced that their marketing authorization application (MAA) for empagliflozin has been accepted for review by the European Medicines Agency (EMA). We note that Eli Lilly is not the only company looking to develop a SGLT-2 inhibitor. In fact, Johnson & Johnson (JNJ - Analyst Report) recently gained FDA approval for its SGLT-2 inhibitor, Invokana.

Eli Lilly currently carries a Zacks Rank #2 (Buy). We are pleased with the company’s efforts to strengthen its diabetes franchise. Eli Lilly’s diabetes franchise consists of products like Humulin, Humalog, and Tradjenta among others.

Last month, Eli Lilly and Boehringer Ingelheim had announced the commencement of a phase IIIb study with Tradjenta in type II diabetes patients with prevalent albuminuria who are currently receiving standard treatment for diabetic nephropathy.

The 24-week, multicenter, multinational, randomized, double-blind, placebo-controlled, parallel-group study, MARINA (efficacy, safety & Modification of Albuminuria in type 2 diabetes subjects with Renal disease with LINAgliptin), will evaluate the glycemic efficacy and safety of once-daily Tradjenta (5 mg). The study is slated to complete in 2014.

Currently, Novo Nordisk (NVO - Analyst Report) also looks well-positioned in the pharma sector with a Zacks Rank #2. Abbott Labs (ABT - Analyst Report) is another company that currently holds a Zacks Rank #2.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UTD THERAPE… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%